Real-world multicenter comparison of effectiveness between tofacitinib and vedolizumab in patients with Ulcerative Colitis after failure to at least one anti-TNF agent

被引：0
|
作者：
Buisson, A. [1 ]
Nachury, M. [2 ]
Fumery, M. [3 ]
Guilmoteau, T. [1 ]
Leclerc, E. [1 ]
Altwegg, R. [4 ]
Serrero, M. [5 ]
Mathieu, N. [6 ]
Treton, X. [7 ]
Vuitton, L. [8 ]
Pereira, B. [9 ]
Amiot, A. [10 ]
Bouguen, G. [11 ]
机构：
[1] Univ Hosp Estaing, Dept Gastroenterol, IBD Unit, Clermont Ferrand, France
[2] CHRU Lille, IBD Unit, Lille, France
[3] CHU Amiens, IBD Unit, Amiens, France
[4] CHU Montpellier, IBD Unit, Montpellier, France
[5] AP HM, IBD Unit, Marseille, France
[6] CHU Grenoble, IBD Unit, Grenoble, France
[7] AP HP Beaujon Hosp, IBD Unit, Paris, France
[8] CHU Besancon, IBD Unit, Besancon, France
[9] Univ Hosp Estaing, DRCI Biostat Unit, Clermont Ferrand, France
[10] AP HP Creteil Hosp, IBD Unit, Paris, France
[11] CHU Rennes, IBD Unit, Rennes, France
来源：
JOURNAL OF CROHNS & COLITIS | 2022年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
DOP76
引用
收藏
页码：I120 / I120
页数：1
相关论文
共 50 条
  • [1] REAL-WORLD MULTICENTER COMPARISON OF EFFECTIVENESS BETWEEN TOFACITINIB AND VEDOLIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS AFTER FAILURE TO AT LEAST ONE ANTI-TNF AGENT
    Buisson, Anthony
    Nachury, Maria
    Fumery, Mathurin
    Guilmoteau, Thomas
    Leclerc, Eloise
    Altwegg, Romain
    Serrero, Melanie
    Mathieu, Nicolas
    Treton, Xavier
    Vuitton, Lucine
    Pereira, Bruno
    Amiot, Aurelien
    Bouguen, Guillaume
    GASTROENTEROLOGY, 2022, 162 (07) : S604 - S604
  • [2] Real-world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti-TNF agent
    Buisson, Anthony
    Nachury, Maria
    Guilmoteau, Thomas
    Altwegg, Romain
    Treton, Xavier
    Fumery, Mathurin
    Serrero, Melanie
    Leclerc, Eloise
    Caillo, Ludovic
    Pereira, Bruno
    Amiot, Aurelien
    Bouguen, Guillaume
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2023, 57 (06) : 676 - 688
  • [3] Real-World Comparison of the Effectiveness between Ustekinumab and Vedolizumab in Patients with Ulcerative Colitis Exposed to at least One Anti-TNF Agent
    Fumery, Mathurin
    Serrero, Melanie
    Bouguen, Guillaume
    Amiot, Aurelien
    Altwegg, Romain
    Nachury, Maria
    Vuitton, Lucine
    Treton, Xavier
    Caillo, Ludovic
    Pereira, Bruno
    Buisson, Antony
    JOURNAL OF CROHNS & COLITIS, 2024, 18 (10) : 1615 - 1621
  • [4] Real-world comparison of effectiveness between tofacitinib and ustekinumab in patients with ulcerative colitis exposed to at least one anti-TNF agent: results from the TORUS study
    Buisson, A.
    Serrero, M.
    Altwegg, R.
    Guilmoteau, T.
    Bouguen, G.
    Nachury, M.
    Amiot, A.
    Vuitton, L.
    Treton, X.
    Caillo, L.
    Pereira, B.
    Fumery, M.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 707 - 707
  • [5] REAL-WORLD COMPARISON OF EFFECTIVENESS BETWEEN TOFACITINIB AND USTEKINUMAB IN PATIENTS WITH ULCERATIVE COLITIS EXPOSED TO AT LEAST ONE ANTI-TNF AGENT: RESULTS FROM THE TORUS STUDY
    Buisson, Anthony
    Serrero, Melanie
    Altwegg, Romain
    Guilmoteau, Thomas
    Guillaume, Bouguen
    Nachury, Maria
    Amiot, Aurelien
    Vuitton, Lucine
    Treton, Xavier
    Caillo, Ludovic
    Pereira, Bruno
    Fumery, Mathurin
    GASTROENTEROLOGY, 2023, 164 (06) : S4 - S4
  • [6] Comparative effectiveness between ustekinumab and vedolizumab after anti-TNF failure in Ulcerative Colitis: Real-world experience
    Jairath, R.
    Zoughlami, A.
    Mahmoud, O.
    Pilote, N.
    Solitano, V
    Mohammad, D.
    Afif, W.
    Bitton, A.
    Wild, G.
    Lakatos, P. L.
    Narula, N.
    Jairath, V
    Bessissow, T.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1186 - i1186
  • [7] Editorial: real-world evidence of tofacitinib and vedolizumab in ulcerative colitis-are we one step closer to better positioning therapies after anti-TNF failure?
    Ernest-Suarez, Kenneth
    Lu, Cathy
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2023, 57 (06) : 733 - 734
  • [8] Real-world Evidence Comparing Tofacitinib and Vedolizumab in Anti-TNF-experienced Patients With Ulcerative Colitis
    Adimadhyam, Sruthi
    Lewis, James D.
    Simon, Andrew L.
    Wolfe, Audrey E.
    Smith, Samantha
    Hou, Laura
    Moyneur, Erick
    Reynolds, Juliane S.
    Toh, Sengwee
    Dobes, Angela
    Parlett, Lauren
    Haynes, Kevin
    Burris, Jessica
    Dorand, Jennifer E.
    Long, Millie D.
    Kappelman, Michael D.
    INFLAMMATORY BOWEL DISEASES, 2024, 30 (04) : 554 - 562
  • [9] Editorial: real-world evidence of tofacitinib and vedolizumab in ulcerative colitis-are we one step closer to better positioning therapies after anti-TNF failure? Authors' reply
    Buisson, Anthony
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2023, 57 (06) : 735 - 736
  • [10] TREATMENT PERSISTENCE RATES WITH TOFACITINIB IN A REAL-WORLD COHORT OF ANTI-TNF REFRACTORY ULCERATIVE COLITIS PATIENTS
    Conley, Thomas
    Colclough, James
    Liu, Eleanor
    Razanskaite, Violeta
    Jakobek, William
    Limdi, Jimmy
    Flanagan, Paul
    Subramanian, Sreedhar
    GUT, 2021, 70 : A88 - A89
12345